Eli Lilly Licenses Inpharmatica's Admensa Interactive
Inpharmatica said this week that Eli Lilly has licensed its Admensa Interactive suite of predictive ADME models and compound-prioritization tools.
"We are delighted that Lilly, with its significant in-house strength in computational ADME, has chosen AI to augment its discovery support," said John Lisle, CEO of Inpharmatica.
Financial terms of the agreement were not disclosed.
Jazz Pharmaceuticals Uses SciTegic's Pipeline Pilot for Sales Support